Semaglutide vs Tirzepatide vs Retatrutide: 14.9% vs 20.9% vs 24.2%, and How to Choose

Semaglutide, tirzepatide, and retatrutide are the three compounds that defined three successive generations of the GLP-1 field, and most people researching this space eventually want the same thing: one page that puts all three side by side. Semaglutide proved a single-receptor incretin drug could produce weight loss an order of magnitude beyond older pharmacotherapy. Tirzepatide added a second receptor and pushed the number further. Retatrutide added a third and pushed it further still, without its trial curve clearly flattening out. ^{[1] [3]}

This is the complete three-way comparison: the trial numbers, the mechanism behind each step up, side effects, dosing, cost and access, evidence maturity, and who each compound actually fits. Everything here reports what the published clinical literature describes; none of it is medical advice, and retatrutide specifically is not approved for human use.

The three-way comparison at a glance

Read left to right and the pattern is consistent: each compound adds one receptor and the mean trial figure climbs with it. Read the bottom two rows and the trade-off is just as consistent in the other direction: the two approved compounds carry a decade-plus evidence base behind them; the newest, highest-scoring compound carries the least.

Which produces the most weight loss: the head-to-head numbers

This is the single most searched question about all three, so start with the actual figures, and the caveat attached to them. Only one pairing here is a genuine head-to-head trial; the rest is cross-trial comparison.

Three things stand out. First, the stepwise pattern across the whole class, one receptor near 15%, two receptors near 21%, three receptors near 24%, is exactly what the multi-receptor thesis predicts, and it holds whether the source trial ran 48, 68, or 72 weeks. Second, retatrutide's 24.2% was measured at the shortest duration of the three (48 weeks) and the trial's own report notes the curve had not clearly plateaued at that point, which if anything understates the true gap at a matched duration. ^[1] Third, retatrutide's lower 8 mg dose (22.8%) already exceeded tirzepatide's top 15 mg dose (20.9%), suggesting the added glucagon receptor is doing real work rather than nudging an already-saturated effect.

The one comparison in this table that is not cross-trial is tirzepatide against semaglutide. SURPASS-2 randomized people with type 2 diabetes directly to tirzepatide or semaglutide 1 mg, and all three tirzepatide doses outperformed semaglutide on both weight loss and glycemic control in the same trial. ^[6] SURMOUNT-5 did the same for an obesity population, randomizing directly to tirzepatide or semaglutide 2.4 mg, and tirzepatide produced significantly greater mean weight loss. ^[7] No trial has yet randomized participants directly to retatrutide against either compound, so every figure involving retatrutide in this article is a cross-trial comparison, not causal proof.

Mono vs dual vs triple agonist: the mechanism behind the numbers

The efficacy ladder traces to a mechanistic fact you can state in one sentence: semaglutide activates one receptor, tirzepatide activates two, retatrutide activates three.

GLP-1 is the shared foundation across all three: it is the incretin hormone that reduces appetite and improves glucose handling, and semaglutide's entire mechanism is built around amplifying that one signal with a long-acting, engineered version of it. ^[9] GIP is tirzepatide's addition, and it appears to work by amplifying GLP-1's effects rather than producing weight loss on its own, which is the leading explanation for why dual agonism outperformed the single-receptor drugs that came before it. ^[5] Glucagon is retatrutide's addition, and it is the genuinely novel part of the class: on its own, glucagon raises blood glucose, which sounds like the wrong direction for a metabolic drug, but paired with strong incretin coverage its useful contribution, increased hepatic energy expenditure and lipid mobilization, is retained while the GLP-1 and GIP arms offset the glycemic penalty. ^[4]

Put simply, each compound keeps everything the previous one had and adds one more lever. Semaglutide pulls the appetite lever. Tirzepatide pulls appetite and an amplifier. Retatrutide pulls appetite, the amplifier, and an energy-expenditure lever that the other two do not touch, which is also the mechanistic explanation for retatrutide's outsized liver-fat reductions in its Phase 2 program. ^{[1] [4]}

Side effects compared: what changes and what stays the same

All three compounds share the same dominant side-effect story, because all three share the GLP-1 mechanism that produces it.

Nausea, diarrhea, constipation, and reduced appetite are the shared headline across all three trials, dose-dependent and concentrated during dose escalation, then easing once the dose stabilizes. ^{[1] [2] [3]} That pattern is a direct extension of GLP-1 receptor activation slowing gastric emptying, the same mechanism that drives the appetite effect, which is why the effects cluster during escalation (when exposure is changing fastest) and settle at a stable dose. This is exactly why all three programs used a stepwise titration schedule rather than starting at the target dose. ^{[1] [2] [3]}

The one profile difference worth naming is retatrutide's dose-dependent skin-sensation effect, dysesthesia, meaning tingling or altered sensation, reported at higher doses in its Phase 2 data. ^[1] This is not a characteristic finding for semaglutide or tirzepatide. As with every figure here, incidence and severity are trial-reported and should be read as study findings, not as an individual prediction.

Dosing and titration compared

On the surface all three are similar to run: once-weekly subcutaneous injections with a multi-week stepwise titration. The differences sit in the specific numbers.

All three cadences exist because all three molecules are engineered the same way: a fatty-acid side chain binds the peptide to circulating albumin, stretching its residence time in plasma from the minutes native incretin hormones last to somewhere between five and seven days, depending on the compound. ^{[4] [5] [9]} The practical consequence is identical across all three: plasma levels build gradually over the first month of dosing and reach steady state in roughly 4 to 5 weeks, so early readings on any of the three systematically understate the eventual effect. The single most common mistake with any of them is reading that quiet first month as failure, which is exactly why trial endpoints for all three were measured at 48 weeks or later, not early. These are reported protocols from the trials, described here as information, not a dosing recommendation.

Cost and access: which is easiest to get

This is where the three diverge most sharply outside the trial data. Semaglutide and tirzepatide are approved medications with established pharmacy supply chains, available by prescription under their brand names, semaglutide as Ozempic (diabetes) and Wegovy (weight management), tirzepatide as Mounjaro (diabetes) and Zepbound (weight management). Pharmacy access typically runs several hundred dollars a month out of pocket without insurance coverage, and eligibility depends on indication and coverage criteria. Both molecules also exist in the research-compound market at substantially lower prices.

Retatrutide is investigational and not approved for any use, so there is no pharmacy route at all for it. It is available only through the research-compound market, which makes sourcing quality the decisive variable for retatrutide in a way it is not for a pharmacy-dispensed drug.

A 99% pure figure is only meaningful if the other 1% is characterized. For any of the three compounds sourced through the research-compound market, the impurity profile, meaning what the non-target fraction actually is, matters as much as the headline number, ideally confirmed by independent third-party testing rather than the manufacturer's numbers alone. Our full standard for evaluating a supplier is documented in how we vet a new manufacturer, and the specifics of sourcing retatrutide are covered in how to get retatrutide in the US.

Evidence maturity: which has the most human data behind it

Efficacy and evidence depth move in opposite directions across these three compounds, and that trade-off is the real decision most people are making.

Semaglutide has the deepest evidence base of the three: four STEP trials plus the SUSTAIN diabetes program plus an oral formulation program (OASIS), and years of post-marketing surveillance under two approved brand names. Tirzepatide is close behind, with a five-trial SURMOUNT obesity program, the SURPASS diabetes program that preceded it, approval under two brand names, and its own post-marketing history, including the SURPASS-2 and SURMOUNT-5 head-to-head trials against semaglutide described above. ^{[6] [7]}

Retatrutide sits at the opposite end. Its Phase 2 obesity trial is complete and is the source of the 24.2% figure used throughout this article, plus a Phase 1b trial in people with type 2 diabetes. ^{[1] [8]} Its Phase 3 program, the TRIUMPH studies, is designed to confirm the Phase 2 signal in larger, longer trials and to characterize safety at scale, but it has not yet reported topline results as of this writing. That is the honest state of the evidence: retatrutide's efficacy signal is the strongest of the three, and its human safety and durability data are the thinnest.

Where cagrilintide fits: a fourth compound in the same conversation

Anyone researching this space long enough runs into a related search: cagrilintide vs tirzepatide vs retatrutide. Cagrilintide is not a GLP-1, GIP, or glucagon agonist at all; it is a long-acting amylin analog, a different hormone target that also contributes to satiety and slowed gastric emptying through a separate receptor pathway. It is being studied both on its own and in fixed combination with semaglutide (as cagrilintide/semaglutide) or with tirzepatide, rather than as a standalone rival to retatrutide's triple-agonist mechanism.

The honest framing for a "cagrilintide vs tirzepatide vs retatrutide" comparison is that it is really two separate questions dressed as one: whether adding an amylin pathway to an existing incretin drug (the cagrilintide-combination approach) can match or exceed what a single multi-receptor molecule like retatrutide achieves. No trial has directly randomized participants across all of these approaches at once, so this remains an open question rather than a settled one, and it is a topic for its own dedicated comparison rather than a full digression here.

The three pairwise match-ups, if you are choosing between just two

Most research decisions come down to two compounds, not three. If that is your actual question, the dedicated head-to-head posts go deeper than this hub can on any single pairing.

Semaglutide vs tirzepatide

The one genuine head-to-head pairing in this whole comparison. SURPASS-2 and SURMOUNT-5 both randomized participants directly to tirzepatide or semaglutide, and tirzepatide won on weight loss and glycemic control in both. ^{[6] [7]} The full breakdown, including dosing and side-effect comparisons, is in tirzepatide vs semaglutide.

Retatrutide vs tirzepatide

The comparison between the current benchmark and the frontier compound: 24.2% versus 20.9% on cross-trial figures, one added glucagon receptor, and a trade-off between retatrutide's stronger signal and tirzepatide's much deeper evidence base. ^{[1] [2]} The full breakdown is in retatrutide vs tirzepatide.

Retatrutide vs semaglutide

The widest efficacy gap of the three pairings, 24.2% versus 14.9%, and the widest gap in receptor count, three versus one. ^{[1] [3]} The full breakdown is in retatrutide vs semaglutide: 24% vs 15%.

Which is right for you: a decision framework

None of these three compounds is universally the right choice. They sit at different points on the same evidence-versus-effect curve.

Framed simply: semaglutide is the reference point, tirzepatide is the proven upgrade, retatrutide is the frontier. Choosing among them is less about which one is objectively best and more about how much unresolved evidence you are willing to trade for a stronger reported effect.

Common myths when comparing these three

"The newest compound is always the strongest" is directionally true here but overstates the certainty: the stepwise pattern (15%, then 21%, then 24%) is a strong signal, not a guarantee that will hold in every population or duration once retatrutide's Phase 3 data reports. "They're all basically the same drug" is a common oversimplification; the receptor table above shows each compound activates a different, specific combination, and those differences are what the trial data attribute the efficacy gaps to. ^{[4] [5]} "Approved means better, investigational means worse" conflates two different things: approval status reflects evidence maturity and regulatory review, not necessarily the underlying effect size, which is exactly why retatrutide can carry the strongest efficacy signal in this comparison while also carrying the least approval status.

Common mistakes people make comparing these three

• Treating cross-trial numbers as a head-to-head result. Only the tirzepatide-versus-semaglutide comparisons (SURPASS-2, SURMOUNT-5) are genuine head-to-head trials; every figure involving retatrutide here is drawn from a separate study. ^{[6] [7]}
• Reading the first month on any of the three as the verdict. All three take about 4 to 5 weeks to reach steady state, so early weeks systematically understate the eventual effect regardless of which compound is being run.
• Ignoring evidence maturity when picking a compound. The strongest trial number and the deepest safety data currently belong to different compounds, and conflating the two leads to an incomplete picture.
• Sourcing any of the three on price alone. An unusually low price on a research compound often reflects skipped independent testing, the exact verification that keeps the label consistent with what is actually in the vial.

The bottom line

On the numbers people search for most, retatrutide leads: 24.2% versus 20.9% versus 14.9%, tracking receptor count exactly across all three compounds. ^{[1] [2] [3]} But only one pairing in that comparison, tirzepatide against semaglutide, comes from an actual head-to-head trial; the rest is a consistent cross-trial signal, not proof. The real decision is not which number is largest but how much depth of human evidence you are willing to trade for it, and each compound sits at a different, defensible point on that trade-off. For the complete picture on any single compound, see the complete retatrutide guide, the complete tirzepatide guide, and the complete semaglutide guide.

For research and educational purposes only. Not medical advice. Trial figures describe published clinical studies; cross-compound comparisons are drawn from separate trials except where a genuine head-to-head trial is named. Semaglutide and tirzepatide are FDA approved under their respective brand names; the compounds discussed and sold here are supplied as research compounds, not as approved pharmaceutical products, and are not intended for human use. Retatrutide is investigational and is not approved for any use.